Clinical trials: Standard treatment
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety…
- Trial name
- NCT02952924
- Testing
- Midazolam, RO7049389
- Where
- 21 sites in Australia, Bulgaria and 6 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Cardiac Surgery Associated - Acute Kidney Injury
Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery
The is a two-stage study. Stage 1 is to evaluate the safety, tolerability, PK and PD of ENN0403 in patients at high risk of AKI following elective cardiac surgery requring cardiopulmonary bypass.
- Trial name
- NCT06632613
- Testing
- ENN0403 capsules, low dose, ENN0403 capsules, high dose
- Where
- China
- Volunteers
- 200 people
- Sponsor
- EnnovaBio
Acute Coronary Syndrome, Myocardial Infarction
A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome
This prospective, non-interventional, single arm, longitudinal cohort multicenter study will recruit approximately 5600 consecutive all-comers, consisting of patients with signs and symptoms of acute coronary syndromes (ACS) who…
- Trial name
- PERFORM-TSIX (NCT06734117)
- Testing
- Elecsys® Troponin T hs Gen 6, Blood sample collection
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 5,429 people
- Sponsor
- Hoffmann-La Roche
Carcinoma in Situ, Transitional Cell Carcinoma
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin…
- Conditions
- Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT01310803
- Testing
- VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Ovarian Neoplasms, Ovarian Cancer (OvCa)
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of progression free survival (PFS).
- Conditions
- Ovarian Neoplasms, Ovarian Cancer (OvCa), Ovarian Epithelial Cancer
- Trial name
- NCT02107950
- Testing
- DCVAC/OvCa in parallel with chemotherapy, Standard of Care
- Where
- 16 sites in Czechia, Germany and 1 more
- Volunteers
- 71 people
- Sponsor
- SOTIO a.s.
Infectious Diseases
Rapamycin and Infection-related Illness
Conduct a 6-month observational pilot clinical trial to evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of medical treatment with oral rapamycin [Rapamune (Sirolimus)] in a total of 15…
- Trial name
- NCT07054320
- Testing
- Observational procedures
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Advanced Cancer, Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced…
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT04354246
- Testing
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy.
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Compugen Ltd
Diabetes Mellitus, Type 2
Diabetes-Specific Formula on Long Term Glycemic Control
The study aims to investigate the effect of a diabetes-specific formula (DSF) used as a (partial) meal replacement on long-term glycemic control and short-term glycemic variability in individuals with type 2 diabetes.
- Trial name
- NCT04345497
- Testing
- Diabetes-Specific Formula, Standard Of Care
- Where
- 5 sites in Malaysia, Thailand
- Volunteers
- 251 people
- Sponsor
- Abbott Nutrition
Crohn Disease
Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)
This is an observational study to determine the prevalence of moderate to severe Crohn's disease (CD) among patients with active CD and to evaluate existing therapeutic trends in a standard clinical practice.
- Trial name
- NCT01218360
- Testing
- Physician standard-of-care
- Volunteers
- 71 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
- Trial name
- NCT04501120
- Testing
- Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT
- Where
- 12 sites in China
- Volunteers
- 682 people
- Sponsor
- Ascentage Pharma Group Inc.
Coronary Artery Disease Progression
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.
- Trial name
- NCT03192579
- Testing
- EPA and high dose rosuvastatin, Standard dose rosuvastatin
- Volunteers
- 50 people
- Sponsor
- Kobe University
Carcinoma, Non-Small-Cell Lung
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
- Trial name
- NCT00415818
- Testing
- MVA-MUC1-IL2, 1st line Chemotherapy
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 148 people
- Sponsor
- Transgene
Advanced Prostate Cancer
Study of XNW5004 Tablets in Advanced Prostate Cancer
Phase Ib A preliminary design of 2 cohorts is planned for this phase, with 3-6 participants to be enrolled in each cohort. A total of 6-12 participants with advanced prostate cancer are planned to be enrolled in this phase.
- Trial name
- XNW5004 Tablet (NCT07730580)
- Testing
- XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID
- Volunteers
- 242 people
- Sponsor
- Evopoint Biosciences Inc.
Elective Cardiac Surgery
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
- Trial name
- REFRESH (NCT02566525)
- Testing
- CytoSorb
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- CytoSorbents, Inc
Systemic Lupus Erythematosus
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active…
- Trial name
- BLISS-52 (NCT00424476)
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Where
- 92 sites in Argentina, Australia and 11 more
- Volunteers
- 865 people
- Sponsor
- Human Genome Sciences Inc.
Solid Tumors
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard…
- Trial name
- NCT02499224
- Testing
- YYB101
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- CellabMED
Head and Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary…
- Trial name
- NCT00198315
- Testing
- Medpulser electroporation with Bleomycin, Tumor surgical excision
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Inovio Pharmaceuticals
Non-Small-Cell Lung Carcinoma NSCLC
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the…
- Trial name
- MYSTIC (NCT02453282)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin
- Where
- 196 sites in United States, Australia and 15 more
- Volunteers
- 1,118 people
- Sponsor
- AstraZeneca
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.